New product developments in whey protein and mobility health

06-Jul-2021 - Last updated on 06-Jul-2021 at 10:16 GMT

Getty | AlexLMX

New product developments in the nutraceuticals space include an ingredient which overcomes taste issues with whey protein hydrolysates and a brand refresh which aims to reframe mobility health products.

Arla Foods Ingredients has launched a new whey protein hydrolysate ingredient that overcomes taste challenges in products for patients with maldigestion or malabsorption.

Whey protein hydrolysates are commonly used in medical nutrition products for people with conditions that impair their ability to digest or absorb protein. However, they commonly have a bitter taste not found in intact whey protein.

To tackle this problem, Arla Foods Ingredients has developed WPH LacprodanDI-3091, an extensively hydrolysed whey protein for medical nutritional supplements. As well as high content of essential amino acids, dipeptides and tripeptides, it offers a significantly better taste profile than similar products.

Produced using a unique enzymatic process, WPH LacprodanDI-3091 has a 21-27% degree of hydrolysis. However, unlike comparable ingredients, it offers minimal off-taste.

Kasper Faarkrog Høyer, Sales Development Manager at Arla Foods Ingredients, says many as a quarter of patients admitted to hospital are malnourished, with the cost to European countries estimated to be as high as €170 billion a year.

“WPH LacprodanDI-3091 offers all the advantages of whey protein hydrolysate, including rapid absorption of nutrients. What distinguishes it is that it combines these benefits with a far better taste than similar ingredients. This means a more pleasurable experience for patients, which is particularly important considering the profound consequences of poor nutritional compliance during recovery.”

The new solution is FSMP (food for special medical purposes)-compliant and can be used in both RTDs and tube feed solutions.

Rebrand moves mobility range into focus

Bioiberica, the Spanish global Life Science company, has launched a new brand identity for its Healthcare branded ingredients portfolio giving customers more well-defined and accessible products, with a clearer "brand architecture".

The re-brand aims to change the way consumers think about joint, muscle and tendon health, with new product names and a new look which brings holistic health into focus.

Bioiberica has renamed its native (undenatured) type II collagen Collavant n2 (previously b-2Cool) and the firm has added Tendaxion - a new brand for its tendon health ingredient - to its portfolio.

These products join Mobilee, a patented hyaluronic acid matrix ingredient, and CSbioactive chondroitin sulfate, to create a consolidated portfolio of new look products for the mobility market.

Jaume Reguant, Director of Healthcare at Bioiberica, says: “Our initial move has been to refocus our mobility ingredients, but this is just the first step of many to offer a more comprehensive portfolio of solutions to our customers. We are constantly investing in our products; the science behind them, our understanding of the target market, and how they should be positioned to help our customers grow their business with truly innovative products.

“Our newly launched brand strategy for our healthcare-oriented ingredients is designed to deliver enhanced co-collaboration opportunities and a stronger foundation on which to build and market products, providing greater potential for growth in new areas – not just for Bioiberica, but our partners, too.”